Cytori Therapeutics Stock Price, News & Analysis (NASDAQ:CYTX)

$0.26 0.03 (12.55 %)
(As of 12/17/2017 07:03 AM ET)
Previous Close$0.26
Today's Range$0.22 - $0.27
52-Week Range$0.22 - $2.13
Volume1.14 million shs
Average Volume823,867 shs
Market Capitalization$9.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CYTX
CUSIP23283K10
Phone858-458-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio0.53%
Quick Ratio0.34%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.66 million
Price / Sales1.96
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book0.51

Profitability

Trailing EPS($0.90)
Net Income$-22,040,000.00
Net Margins-367.33%
Return on Equity-228.21%
Return on Assets-69.19%

Miscellaneous

Employees65
Outstanding Shares35,120,000

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics shares reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.02. The biotechnology company earned $1.77 million during the quarter, compared to analysts' expectations of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same period last year, the business earned ($0.26) earnings per share. View Cytori Therapeutics' Earnings History.

When will Cytori Therapeutics make its next earnings announcement?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 22nd 2018. View Earnings Estimates for Cytori Therapeutics.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

2 brokerages have issued 12 month target prices for Cytori Therapeutics' shares. Their forecasts range from $2.30 to $5.00. On average, they anticipate Cytori Therapeutics' share price to reach $3.65 in the next year. View Analyst Ratings for Cytori Therapeutics.

What are Wall Street analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • 1. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)
  • 2. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (11/9/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:

  • David M. Rickey, Independent Chairman of the Board (Age 59)
  • Marc H. Hedrick M.D., President, Chief Executive Officer, Director (Age 52)
  • Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance (Age 35)
  • Seijiro N. Shirahama, President , Asia Pacific (Age 60)
  • John David Harris, Vice President, General Manager - Cell Therapy
  • Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
  • Mark Marino M.D., Chief Medical Officer
  • Gregg A. Lapointe, Director
  • Richard James Hawkins, Independent Director (Age 68)
  • Gary A. Lyons, Independent Director (Age 66)

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of Cytori Therapeutics stock can currently be purchased for approximately $0.26.

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $9.13 million and generates $4.66 million in revenue each year. The biotechnology company earns $-22,040,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Cytori Therapeutics employs 65 workers across the globe.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]


MarketBeat Community Rating for Cytori Therapeutics (CYTX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytori Therapeutics (NASDAQ:CYTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.10$6.10$6.10$7.77
Price Target Upside: 1,548.65% upside1,548.65% upside1,699.64% upside676.67% upside

Cytori Therapeutics (NASDAQ:CYTX) Consensus Price Target History

Price Target History for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ:CYTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017Maxim GroupSet Price TargetBuy$5.00N/AView Rating Details
11/7/2017B. RileyReiterated RatingHoldN/AView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Cytori Therapeutics (NASDAQ:CYTX) Earnings History and Estimates Chart

Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ CYTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2018        
11/9/2017Q3 17($0.16)($0.14)$2.04 million$1.77 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.16)($0.18)$2.23 million$0.90 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cytori Therapeutics (NASDAQ:CYTX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.10)($0.10)($0.10)
Q2 20181($0.04)($0.04)($0.04)
Q3 20181($0.04)($0.04)($0.04)
Q4 20181($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytori Therapeutics (NASDAQ:CYTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytori Therapeutics (NASDAQ CYTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 7.41%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ CYTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytori Therapeutics (NASDAQ CYTX) News Headlines

Source:
DateHeadline
Financial Analysis: Haemonetics (HAE) & Cytori Therapeutics (CYTX)Financial Analysis: Haemonetics (HAE) & Cytori Therapeutics (CYTX)
www.americanbankingnews.com - December 16 at 1:34 PM
Head-To-Head Analysis: Cytori Therapeutics (CYTX) and Symmetry Medical (SMA)Head-To-Head Analysis: Cytori Therapeutics (CYTX) and Symmetry Medical (SMA)
www.americanbankingnews.com - December 12 at 3:24 AM
ETFs with exposure to Cytori Therapeutics, Inc. : December 8, 2017ETFs with exposure to Cytori Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:10 PM
Cytori Therapeutics (CYTX) & Inogen (INGN) Critical ComparisonCytori Therapeutics (CYTX) & Inogen (INGN) Critical Comparison
www.americanbankingnews.com - December 5 at 1:38 AM
Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?
finance.yahoo.com - November 30 at 5:12 PM
Cytori Closes Rights Offering for Gross Proceeds of $10 Million - GlobeNewswire (press release)Cytori Closes Rights Offering for Gross Proceeds of $10 Million - GlobeNewswire (press release)
globenewswire.com - November 29 at 5:35 PM
Cytori Closes Rights Offering for Gross Proceeds of $10 MillionCytori Closes Rights Offering for Gross Proceeds of $10 Million
finance.yahoo.com - November 28 at 5:16 PM
ETFs with exposure to Cytori Therapeutics, Inc. : November 27, 2017ETFs with exposure to Cytori Therapeutics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 6:06 PM
Analyzing VWR (VWR) and Cytori Therapeutics (CYTX)Analyzing VWR (VWR) and Cytori Therapeutics (CYTX)
www.americanbankingnews.com - November 26 at 3:48 AM
Cytori Announces Expiration of Oversubscribed Rights Offering - GlobeNewswire (press release)Cytori Announces Expiration of Oversubscribed Rights Offering - GlobeNewswire (press release)
globenewswire.com - November 24 at 4:06 PM
Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 21 at 5:59 PM
Cytori Therapeutics (CYTX) Announces Reduction in Fibrosis ... - StreetInsider.comCytori Therapeutics (CYTX) Announces Reduction in Fibrosis ... - StreetInsider.com
www.streetinsider.com - November 21 at 4:47 AM
Cytori Reports Reduction in Fibrosis Parameters in Scar StudyCytori Reports Reduction in Fibrosis Parameters in Scar Study
finance.yahoo.com - November 20 at 6:43 PM
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS - GlobeNewswire (press release)Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS - GlobeNewswire (press release)
globenewswire.com - November 16 at 6:18 PM
Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21
finance.yahoo.com - November 16 at 1:17 PM
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPSCytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
finance.yahoo.com - November 16 at 1:17 PM
Analyzing Cytori Therapeutics (CYTX) and Its CompetitorsAnalyzing Cytori Therapeutics (CYTX) and Its Competitors
www.americanbankingnews.com - November 16 at 11:38 AM
Maxim Group Analysts Give Cytori Therapeutics Inc (CYTX) a $5.00 Price TargetMaxim Group Analysts Give Cytori Therapeutics Inc (CYTX) a $5.00 Price Target
www.americanbankingnews.com - November 13 at 5:12 PM
Cytori Announces New U.S. Investigator Trial for Hip OsteonecrosisCytori Announces New U.S. Investigator Trial for Hip Osteonecrosis
finance.yahoo.com - November 13 at 12:26 PM
Cytori Therapeutics Inc (CYTX) Short Interest UpdateCytori Therapeutics Inc (CYTX) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
EARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q3 Earnings Report
www.rttnews.com - November 10 at 5:44 PM
Cytori Therapeutics (CYTX) versus Integra LifeSciences Holdings Corporation (IART) Critical ContrastCytori Therapeutics (CYTX) versus Integra LifeSciences Holdings Corporation (IART) Critical Contrast
www.americanbankingnews.com - November 10 at 5:26 PM
Cytori Reports Third Quarter 2017 Business and Financial ResultsCytori Reports Third Quarter 2017 Business and Financial Results
finance.yahoo.com - November 10 at 8:43 AM
Cytori reports 3Q lossCytori reports 3Q loss
finance.yahoo.com - November 10 at 8:43 AM
Edited Transcript of CYTX earnings conference call or presentation 9-Nov-17 10:30pm GMTEdited Transcript of CYTX earnings conference call or presentation 9-Nov-17 10:30pm GMT
finance.yahoo.com - November 10 at 8:43 AM
Cytori Therapeutics Inc (CYTX) Issues  Earnings ResultsCytori Therapeutics Inc (CYTX) Issues Earnings Results
www.americanbankingnews.com - November 9 at 11:44 PM
Zacks Investment Research Downgrades Cytori Therapeutics Inc (CYTX) to SellZacks Investment Research Downgrades Cytori Therapeutics Inc (CYTX) to Sell
www.americanbankingnews.com - November 9 at 6:28 PM
Q3 2017 EPS Estimates for Cytori Therapeutics Inc (CYTX) Lowered by AnalystQ3 2017 EPS Estimates for Cytori Therapeutics Inc (CYTX) Lowered by Analyst
www.americanbankingnews.com - November 9 at 6:20 AM
STAR Trial Data Accepted for Presentation at Systemic Sclerosis World CongressSTAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress
finance.yahoo.com - November 8 at 2:07 AM
ETFs with exposure to Cytori Therapeutics, Inc. : November 6, 2017ETFs with exposure to Cytori Therapeutics, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 7:03 PM
Cytori Therapeutics Inc (CYTX) Scheduled to Post Quarterly Earnings on ThursdayCytori Therapeutics Inc (CYTX) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - November 3 at 10:59 AM
Cytori to Webcast Third Quarter Financial Results on November 9Cytori to Webcast Third Quarter Financial Results on November 9
finance.yahoo.com - November 2 at 6:43 PM
Analyzing Cytori Therapeutics (CYTX) and Its PeersAnalyzing Cytori Therapeutics (CYTX) and Its Peers
www.americanbankingnews.com - November 2 at 2:04 PM
Cytori Therapeutics Inc (CYTX) Short Interest Up 59.9% in OctoberCytori Therapeutics Inc (CYTX) Short Interest Up 59.9% in October
www.americanbankingnews.com - October 27 at 1:40 AM
Baxter International (BAX) versus Cytori Therapeutics (CYTX) Critical ReviewBaxter International (BAX) versus Cytori Therapeutics (CYTX) Critical Review
www.americanbankingnews.com - October 26 at 11:18 PM
Cytori Therapeutics (CYTX) versus Its Rivals Head-To-Head AnalysisCytori Therapeutics (CYTX) versus Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - October 26 at 11:18 PM
ETFs with exposure to Cytori Therapeutics, Inc. : October 26, 2017ETFs with exposure to Cytori Therapeutics, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 2:21 PM
Maxim Group Reiterates $5.00 Price Target for Cytori Therapeutics Inc (CYTX)Maxim Group Reiterates $5.00 Price Target for Cytori Therapeutics Inc (CYTX)
www.americanbankingnews.com - October 22 at 2:44 PM
DENTSPLY SIRONA (XRAY) vs. Cytori Therapeutics (CYTX) Head to Head ReviewDENTSPLY SIRONA (XRAY) vs. Cytori Therapeutics (CYTX) Head to Head Review
www.americanbankingnews.com - October 21 at 4:40 AM
Should You Buy Cytori Therapeutics Inc (CYTX) Now?Should You Buy Cytori Therapeutics Inc (CYTX) Now?
finance.yahoo.com - October 17 at 6:33 PM
Todays Research Reports on Trending Tickers: Cytori Therapeutics and Repros TherapeuticsToday's Research Reports on Trending Tickers: Cytori Therapeutics and Repros Therapeutics
finance.yahoo.com - October 9 at 6:08 PM
ETFs with exposure to Cytori Therapeutics, Inc. : October 9, 2017ETFs with exposure to Cytori Therapeutics, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 6:08 PM
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics - PR Newswire (press release)Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics - PR Newswire (press release)
www.prnewswire.com - October 3 at 7:36 AM
ETFs with exposure to Cytori Therapeutics, Inc. : September 27, 2017ETFs with exposure to Cytori Therapeutics, Inc. : September 27, 2017
finance.yahoo.com - October 3 at 7:36 AM
ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 5:50 PM
Cytori to restructure, cut 50% of workforce - Seeking AlphaCytori to restructure, cut 50% of workforce - Seeking Alpha
seekingalpha.com - September 1 at 6:03 PM
Cytori Announces Corporate Restructuring & Cost Reduction PlanCytori Announces Corporate Restructuring & Cost Reduction Plan
finance.yahoo.com - September 1 at 6:03 PM
ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 7:19 PM
Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD TreatmentBiotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment
finance.yahoo.com - August 17 at 7:00 PM
Cytori Therapeutics (CYTX) Neutral Rating Reaffirmed at B. RileyCytori Therapeutics' (CYTX) Neutral Rating Reaffirmed at B. Riley
www.americanbankingnews.com - August 16 at 10:56 PM

SEC Filings

Cytori Therapeutics (NASDAQ:CYTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytori Therapeutics (NASDAQ:CYTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytori Therapeutics (NASDAQ CYTX) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.